F.E.C.C.I.A.
Fédération Européenne des Cadres de la Chimie
et des Industries Annexes
56, rue de Batignolles
F-75017 PARIS
tel.: 33 1 42 28 28 05
fax: 33 1 42 28 12 99

 

 

FECCIA Steering Committee

Köln, on 29 September 2001

Statement of the President François Vincent

 

 

World and European Chemical Industry

The optimism of the year 2000 has receded and numerous Chemical Companies have issued profit warnings since the beginning of the year. Declining results for the first half of 2001 and revisions to the forecast decline of results for the whole year are increasing, except for Groups with dominant pharmaceutical interests.

The main reason is the increase of the oil price to 25 dollars per barrel, that increases the price of the chemical industry's raw materials. The slowing of American economic activity (with an exceptionally high gas price) entails a slowing of growth and pressure on prices as margins decrease on a long-term basis in all intermediate products with high energy content. The increase in the exchange rate of the euro against the dollar will slow down exports that are always a source of important income for the European Chemistry.

The American Chemical Industry is expected to fall 0,3% (volume) this year, as well as the Japanese Chemical Industry 0,5%. The Asian Chemical Industry found again its dynamism with a growth of 7-8% in 2001 and 2002. In stock markets, as the new economy collapsed, Pharmaceuticals served a as refuge to investors. Another very solid sector was oil, where majors strengthened their positions in 2000 and continue to make important profits.

Diversified Chemical Companies continue to report weak figures with stock values well below the leaders. The top five diversified chemical groups (Du Pont, Bayer, BASF, Dow, Akzo Nobel) have a stock value / turnover ratio of 1,3 while the top five mainly-pharmaceutical groups (Pfizer, Merck, GSK, J&J, Novartis) have the same ratio equal to 6,0.

The Speciality Chemicals, launched with media fanfares, is not living up to its promises and concerned groups do not resist the current slowing of growth, as well as of the economic climate (rise of the cost of raw materials and energy).

ICI, one of the original leaders of the world Chemical Industry, put up a good resistance and its CEO ensures that measures are taken in order that the Group improves its performances.

Rhodia, previous number one of the French Chemical Industry, had a disappointing first half year.

A new logo and corporate design have been developed for CEFIC. The former is to show the evolution of the organisation to one with dynamic attitude and objectives, reinforcing a new mode of work, more open and more direct with its members.

Jean-Pierre Tirouflet, President of CEFIC, is resolutely optimistic for the growth of European chemical industry: 3,6% in 2000, 2% in 2001 and 3% in 2002.

Restructurings

Splits and mergers continue in all areas of the chemical industry (see annex)

GlaxoSmithKline (GSK) is as big as Pfizer, number one of the pharmaceuticals.

DuPont sold its oil sector at a bad moment.

Dow is confident in its merger with Union Carbide, but transaction and restructuring costs are high (1,4 billion dollars).

BASF sold its pharmaceuticals to the profit of the group Abbott with an exceptional appreciation of 6 billions euros on an amount of transfer of 6,9 billion dollars.

Syngenta was created as world leader in Agrochemicals, with a great number of jobs suppressed. Aventis sold its Crop Science division to BAYER, after having abandoned the concept of "Life Sciences" and after the resignation of its CEO, Alain Godard. However Bayer, that wanted to preserve its diversified structure, was in difficulty because of problems with a drug and announced a change in strategy.

Atofina is the result of the rearrangement of the chemical activities of Elf, Fina and Total with a reorganization in depth and the suppression of a research center.

EON, which is refocussing on its energy activities, is ready to sell its chemical activity Degussa, born of the fusion of Degussa-Hüls and SKW Trostberg.

Sanofi-Synthelabo displays a dynamic growth of its new products and L’Oréal continues to be a model Company in the sector of Cosmetics.

Environment and health

Chemicals has to face the emergence of new environment constraints coming from international regulations:

  1. UNO : Stockholm Convention on POPs
  2. The United Nations Environment Programme (UNEP) works to protect human health and the environment world-wide, and UNEP Chemicals is the main catalytic force in the UN system for concerted global action on the environmentally sound management of hazardous chemicals. Located in Geneva, Switzerland, UNEP promotes sustainable development by catalysing vital global actions.

    On 22 May 2001, 127 governments adopted the Stockholm Convention on Persistent Organic Pollutants (POPs). POPs are chemicals that are persistent, bioaccumulate in fatty tissues, biomagnify through the food chain and adversely affect health and the environment. The adoption of the Convention and its subsequent signing by 92 parties signaled the end of negotiations that started in June 1998. These negotiations were called for in 1997 by the Governing Council of UNEP in recognition of the need for urgent global action to protect human health and the environment from POPs.

    The Convention seeks the elimination or restriction of production and use of all intentionally produced POPs (i.e., industrial chemicals and pesticides). Initially, the chemicals listed for elimination are aldrin, chlordane, dieldrin, endrin, heptachlor, hexachlorobenzene (HCB), mirex, toxaphene, polychlorinated biphenyls (PCBs). Continued use of DDT is allowed for vector control until safe, affordable and effec-tive alternatives are in place. Countries must make determined efforts to identify, label and remove PCB-containing equipment from use by 2025, and manage those wastes in an environmentally sound manner no later than 2028.

    The Convention also seeks the continuing minimization and, where feasible, ultimate elimination of the releases of unintentionally produced POPs such as dioxins and furans. Stockpiles and wastes containing POPs must be managed and disposed of in a safe, efficient and environmentally sound manner, taking into account international rules, standards and guidelines. Each Party is required to develop a plan for implementing its obligations under the Convention.

    The Convention also imposes certain trade restrictions, and has a procedure for adding other POPs. Governments have set up an interim financial mechanism, with the Global Environment Facility (GEF) as the principal entity, to assist developing countries and countries with economies in transition in their implementation of the treaty.

  3. European Commission: White paper

The Commission sets out the path towards a sustainable use of chemicals

On 13th February, 2001, the European Commission adopted a White Paper setting out the strategy for a future Community Policy for Chemicals. The main objective of the new Chemical Strategy is to ensure a high level of protection for human health and the environment, while ensuring the efficient functioning of the internal market and stimulating innovation and competitiveness in the chemical industry. Commenting on today's announcement Environment Commissioner Margot Wallström said: "This is one of the most important initiatives the Commission has taken in the context of sustainable development. We have decided on a step-by-step approach to phase out and substitute the most dangerous substances – the ones that cause cancer, accumulate in our bodies and in our environment and affect our ability to reproduce. This decision is crucial for future generations".

Enterprise Commissioner Erkki Liikanen said: "Today's decision is crucial to get good and reliable information on the basis of which we can start analysing the many chemicals on the market on which we have no knowledge of their effects on the environment and our health. At the same time the decision is important to create a proper internal market for chemicals products – and thus a level playing field for our industry. The scheme which we have agreed today will also help stimulating innovation and will provide industry a clear framework within which they can work on a competitive footing with other global players.

Chemical companies are anxious

Of the 30,000 chemical substances currently sold, 80% are produced in very small quantity (less than 100 tons per year) and are judged inoffensive. For these substances, manufacturers will have simply to bring "more information" by 2012, the European Commission white paper recommends. But, for 15% of these 30,000 products, i.e. approximately 5,000 substances manufactured in quantities over 100 tons and suspected to be potentially harmful, the future is quite different.

To continue to sell some ethers, gas or chlorinated products, manufacturers will have, for example, to conduct thorough tests (by 2005 when the production exceeds 1,000 tons and by 2008 when it exceeds 100 tons) so as to prove that they are harmless in the long term. This will cost the manufacturers approximately 2 billion euros in total.

For the remaining 5%, i.e. 1,500 products, a withdrawal or a severe restriction of marketing are already counselled by the white paper. It concerns substances judged potentially carcinogenic, eg asbestos or benzene, mutagenic or toxic to reproduction, or extremely polluting. The objective is to replace them rapidly by less harmful products.

CEC / European Commission / European Parliament

European Company Directive

The European Parliament debated the proposed Directive on the European Company. The European Confederation of Managers (CEC) met the German Rapporteur Winfried Menrad to explain its position, and to insist on the capacity of specific representation of managers. It proposed amendments to achieve this.

Corporate Social Responsibility : Green Paper

Commission urges greater Corporate Social Responsibility in Europe

Shortly after the European Commission's communication on quality of work, Commissioners Anna Diamantopoulou (Employment and Social Affairs) and Erkki Liikanen (Enterprise and Information Society) presented a Green Paper on promoting a European framework for Corporate Social Responsibility , whereby companies decide voluntarily to contribute to a better society. The paper, intended as a launch pad for debate, takes up the "triple bottom line" concept, whereby companies voluntarily take on board social and environmental concerns besides their economic ones. In line with the Commission's proposal for a Sustainable Development Strategy for Europe, recently endorsed by the Gothenburg European Council, the paper argues that all three elements can dovetail to create more productive and profitable business. Announcing its publication, Commissioners Diamantopoulou and Liikanen said, "More and more firms are realising the link between profitability and best ethical and environmental practice. Conscientious firms not only attract and retain the best workers, they can also get ahead in the technology game, vital for that all-important competitive edge." The paper is a direct contribution to the goal, backed by EU leaders at the March 2000 Lisbon European Council, of making the EU "the most competitive and dynamic knowledge-based economy in the world, capable of sustainable economic growth with more and better jobs and greater social cohesion." Part of this challenge lies in combining business profitability with the twin concepts of sustainability and accountability. It is also about striking the appropriate balance between flexibility and responsibility in creating a business-friendly environment.

Protection of workers' personal data

First stage consultation of social partners

The purpose of this document is to consult the social partners, in accordance with Article 138, paragraph 2 of the EC Treaty, on the possible direction of a Community action on the protection of workers' personal data.

Employers collect personal data on job applicants and workers for a number of purposes, including to comply with law, to assist in selection for employment, training and promotion, to ensure personal safety, personal security, quality control, customer service and the protection of property.

Directive 95/46/EC fully applies to workers' personal data. However, it could be argued that, given the specific nature of the employment relationship and considering the general nature of the Directive, there may be a need for detailing out the application of the principles in the employment context.

Financial participation: Consultation of CEC by the European Commission

The Social Policy Agenda adopted by the European Commission on 28 June 2000 states (point 4.1.2.2) that a communication on financial participation and an action plan will be prepared in 2001.

The purpose of financial participation is to associate a company’s employees with its profits and/or results. Financial participation schemes can take different forms. They may apply to senior managers or to all staff.

The Commission is interested in particular in the schemes that apply to all a company’s workers or, at any rate, to the great majority.

This paper classifies such schemes under three headings: profit sharing, share ownership and share options.

  1. Profit sharing implies the sharing of profits by providers of both capital and labour, by giving employees, in addition to a fixed wage, a variable income directly linked to profits or some other measure of enterprise results.
  2. Employee share ownership provides for employee participation in enterprise results in an indirect way, i.e. on the basis of participation in ownership, either by receiving dividends, or the appreciation of employee-owned capital after the selling of the shares, or a combination of the two.
  3. Share options give employees an option to buy company shares at a certain price (normally at or below the market price at the time the option is granted) for a specified period of time. In the past, schemes have been targeted mainly at senior management, but they are increasingly being opened up to a wider group or even to all employees.

.

Contacts with European Groups

  1. Aventis
  2. FECCIA signed two protocols:

    • On the installation of the Committee of European enterprise, with participation of French managers as member of the committee
    • On the participation of a Manager to the Supervisory Board of Aventis, mandated by FECCIA. The first mandate is assumed by Joachim Betz, that is furthermore President of VAA.

  3. TotalFinaElf
  4. FECCIA was able to designate a manager CNC / NCK as member of the Special Group of Negotiation and signed the protocol of agreement. However, on the constitution of the Belgian delegation to the European Council, the CNC / NCK could not participate in the negotiation nor present a candidate. The President of FECCIA and the President of CNC/NCK have met the Belgian Direction of Human Resources, to attempt to find a solution, without success !

  5. Syngenta
  6. A meeting between a British AMPS member, manager in AstraZeneca and a member French of FCC, employee in the crop sector of Novartis, took place in Paris to prepare the merging of activities in the new Company Syngenta. Contacts have been continued during the constitution of the European Works Council of Syngenta.

 

 

Annex

 

PRINCIPALES FUSIONS, ACQUISITIONS OU CESSIONS ANNONCEES OU FINALISEES EN 2000

SOCIETES CONCERNEES

CA CONCERNE

MONTANT DE LA TRANSACTION

MARCHES ET OBJECTIFS DE L'OPERATION

PAYS D'ORIGINE

DATE DE L'ANNONCE

DATE DE BOUCLAGE DE L'OPERATION

Pfizer/ Warner Lambert

30 Mrds $

90 Mrds $

Naissance du n°1 mondial ; croissance supérieure à 10%/an

US/US

1999

2000

Glaxo Welcome/ SmithKline Beecham

25 Mrds $

-

Naissance de GlaxoSmithKline (GSK), le coleader mondial de l'industrie pharmaceutique

US/UK

1999

2000

Pharmacia Upjohn/ Monsanto

16,5 Mrds $

27 Mrds $

Le nouveau Pharmacia se recentre sur la pharmacie tandis que Monsanto met en Bourse son agrochimie

US/US

1999

2000

Dow Chemical/ Union Carbide

24 Mrds $

11,6 Mrds $

Fusion des deux groupes chimiques

US/US

1999

Objectif Mars 2001

Sumitomo Chemical/ Mitsui Chemical

16 Mrds $

joint-venture

Création du n°1 de la chimie asiatique et n°5 mondial

Jap./Jap.

2000

2003

TotalFina/Elf

16 Mrds $

joint-venture entre les maisons mères

Création d'Atofina, 5ème chimiste mondial

F/F

1999

2000

Degussa Hüls/ SKW Trotsberg

14 Mrds €

12 Mrds €

Constitution d'un "nouveau" Degussa qui se situe aux premières places mondiales de la chimie de spécialités

D/D

1999

2000

Abbott/Knoll

2,6 Mrds $

6,9 Mrds $

Cession par BASF de sa pharmacie

US/D

2000

2000

Shire Pharma/ Biochem

600 M $

4 Mrds $

Concentration dans la pharmacie

UK/Can.

2000

2000

Degussa/Laporte

650 M €

2,3 Mrds €

Degussa se renforce dans la chimie fine, notamment pour la pharmacie

D/UK

2000

2001

Clariant/BTP

500 M $

1,8 Mrds $

Renforcement dans la chimie fine pharmaceutique et agrochimique

CH/UK

2000

2000

Invitrogen/Dexter

500 M $

1,78 Mrds $

Acquisition de technologies pharmaceutiques

US/US

2000

2000

AEA Investors/ Goodrich Performance Materials

1,2 Mrds $

1,4 Mrds $

Acquisition par un groupe financier

US/US

2000

2001

Rhodia/ Albright & Wilson

6 Mrds $

1,1 Mrds $

Position de leader mondial dans les phosphates

F/UK

1999

2000

BP Amoco/ Burmah Castrol

4,3 Mrds $ (Burma Cast.)

4,7 Mrds $

Acquisition d'activités dans les lubrifiants et la chimie de spéc.

UK/UK

2000

2000

Chevron/Philips

6 Mrds $

joint-venture dans la chimie

Constitution d'un groupe de taille mondiale dans la pétrochimie, les oléfines, les aromatiques, les matières plastiques

US/US

2000

2000

BASF/ Shell Chemicals

6 Mrds $

joint-venture dans les polyoléfines

Basell devient le leader mondial des polyoléfines

D/UK/NL

1999

2000

Linde/Aga

1,8 Mrds €

3,5 Mrds €

Concentration dans les gaz industriels

D/S

1999

2000

BP Chemicals/ Solvay

2,5 Mrds €

Cession du PP et joint-venture dans le PEHD

Solvay sort du PP et met son PEHD en JV avec BP

UK/B

2000

2001

Rhodia/Chirex

150 M $

0,5 Mrd $

Renforcement de Rhodia dans la chimie fine pharmaceutique

F/US

2000

2000

DSM/Catalytica

450 M $

800 M $

DSM se renforce dans la chimie fine pharmaceutique sur le marché US

NL/US

2000

2001

IFF/BBA

2 Mrds $

970 M $

Acquisition qui permet à IFF de repasser en n°1 devant de repasser en n°1 devant Givaudan

US/US

2000

2001

Novartis/AstraZeneca

7 Mrds $

joint-venture

Devient le leader détaché en agrochimie et n°3 en semences. Permet à Norvartis et AstraZeneca de sortir de l'agrochimie

CH/UK

1999

2000

Sasol/Condea

4 Mrds $

1,16 Mrds $

Leader mondial des tensio-actifs, avec une bonne intégration amont

SA/D

2000

2001

ICI/activités chimiques

cessions

Env. 1 Mrd €

Méthanol à Methanex Participation dans HICI à Huntsman. Chlore et HFC à Ineos

UK/Can. /UK/UK

1999

2000

Pierre Fabre/BioMérieux

1,75 Mrds €

joint-venture

Création d'un groupe présent dans le médicament, la dermo-cospique, le diagnostic, l'homéopathie

F/F

2000

2001

Wacker/Wacker

3 Mrds €

n.c.

Cession à la famille Wacker par Aventis de sa participation de 50 % dans le groupe Wacker

D/D

2000

2001

Bayer/ polyols de Lyondell

2,45 Mrds $

Renforce les positions de Bayer dans le PUR

D/US

1999

2000

KKR/Chimie de spécial. de Laporte

726 M $

1,18 Mrd $

Acquisition par un groupe financier

US/UK

2000

2000

Morgan Grenfell/ epoxy de Ciba

1 Mrd $

950 M $

Acquisition par un groupe financier

D/CH

1999

2000

Industri Kapital/Dyno

1,2 Mrd $

595 M $

Acquisition par un groupe financier

N/N

1999

2000